Recent 8-K filings for KEQU
Highest-materiality recent filing
Kewaunee Scientific acquires Nu Aire for $55M; expands life sciences product line
- Total purchase price $55M, funded with $32M cash (PNC revolver & term loan) and $23M seller notes at 8%.
- PNC financing includes $20M revolver and $15M term loan maturing Nov 2029; seller notes mature in 3 years.
-
Kewaunee Scientific sets Q4 and FY2026 earnings release for June 23
Results for quarter and fiscal year ended April 30, 2026 will be released after market close on June 23, 2026.
-
Kewaunee Scientific Q3 sales +3.3% to $69.4M; diluted EPS $0.23 vs $0.45; backlog down 17% YoY
Sales $69.4M (+3.3% YoY); pre-tax earnings $1.6M (+25.8%).
-
Kewaunee Scientific sets Q3 FY2026 earnings release for March 11, 2026
Earnings release scheduled for Wednesday, March 11, 2026 after market close.
-
Kewaunee Scientific Q2 FY2026: sales +46.8% to $70.1M, diluted EPS $0.82 vs $1.01
Sales up 46.8% to $70.1M; net earnings $2.45M (-18.7%); diluted EPS $0.82 (vs $1.01).
-
Kewaunee repays $23M seller notes early with new $10M term loan and revolver draw
Entered First Amendment with PNC Bank for additional $10M term loan and revolver access to fund repayment.
-
Kewaunee Scientific sets Q2 FY2026 earnings release for December 10, 2025
Company will release Q2 fiscal 2026 results on December 10, 2025 after market close.
-
Kewaunee Scientific appoints J. Jette Campbell as Class II director; bylaws amended for board size
J. Jette Campbell appointed to Board of Directors, effective Sept. 10, 2025; term expiring at 2027 annual meeting.
-
Kewaunee Scientific Q1 sales up 47%; EPS $1.04; backlog $205M; expects FY EBITDA increase
Sales $71.1M (+46.9% YoY); diluted EPS $1.04 vs $0.74; net earnings $3.09M.
-
Margaret B. Pyle and Donald F. Shaw were re-elected as Class III directors with 1,633,067 and 1,730,171 votes for, respectively.
-
Kewaunee Scientific announces Q1 FY2026 earnings release date of Sept 10, 2025
First quarter fiscal 2026 results to be released on Wednesday, September 10, 2025 after market close.
-
Kewaunee Scientific posts investor presentation for annual meeting
Company posted investor presentation and script on its website under Investor Information.
-
Kewaunee Scientific Q4 sales up 36% to $77.1M; EPS $1.63, backlog $214.6M
Q4 sales $77.1M, +36% YoY; pre-tax earnings $7.1M vs $1.3M prior year quarter (which included non-recurring pension charge).
-
Kewaunee Scientific to report Q4 and FY2025 results on June 25, 2025
Results for fourth quarter and fiscal year ended April 30, 2025 to be released June 25 after market close.
-
Kewaunee Q3 revenue +44% to $67.2M; adj. diluted EPS $1.09 vs $0.85
GAAP diluted EPS $0.45 vs $0.85; net earnings $1.4M vs $2.5M; includes $2.5M Nu Aire acquisition & integration costs.
-
Kewaunee Scientific expands share repurchase authorization by 100,000 shares
Board authorized repurchase of up to additional 100,000 shares under existing program; no expiration date.
-
Kewaunee Scientific sets Q3 FY2025 earnings release for March 12, 2025
Company will release Q3 FY2025 financial results after market close on Wednesday, March 12, 2025.
-
Kewaunee closes Nu Aire acquisition for $55M; audited Nu Aire FY24 net income $5.44M
Kewaunee acquired Nu Aire for $55M on Nov 1, 2024, using $35M bank financing and $23M seller notes at 8%.
-
Net sales $47.8M (down 5.3% YoY); domestic sales up 6.5%, international down 30.1% due to India construction delays.
-
Kewaunee Scientific announces Q2 FY2025 earnings release date: Dec 11, 2024
Earnings will be released after the close of trading on December 11, 2024.
-
Kewaunee Scientific acquires Nu Aire for $55M; expands life sciences product line
Total purchase price $55M, funded with $32M cash (PNC revolver & term loan) and $23M seller notes at 8%.
-
Kewaunee Scientific Q1 FY2025 sales down 2.9%, EPS $0.74 vs $0.86, backlog up 13%
Sales $48.4M, down 2.9% YoY; diluted EPS $0.74 vs $0.86 in prior year quarter.
-
Kewaunee Scientific shareholders re-elect director, ratify auditor, approve say-on-pay
Director Keith M. Gehl re-elected with ~1.4M votes for, 273K withheld, 740K non-votes.
-
Kewaunee Scientific to release Q1 FY2025 earnings on September 11, 2024
Results will be reported after market close on Wednesday, September 11, 2024.
-
Kewaunee Scientific posts investor presentation for annual meeting; no material new info disclosed
Company held virtual annual shareholder meeting on August 28, 2024.
-
Kewaunee Q4 sales up 5%, adjusted EPS $1.55 vs $0.34; backlog rises to $155.6M
Q4 sales $56.7M (+5% YoY); GAAP net earnings $11.0M (diluted EPS $3.71) include two non-recurring items.
-
Kewaunee Scientific schedules Q4/fiscal year 2024 earnings release for June 26
No financial results or guidance provided in this filing; only the release date is announced.
-
Kewaunee Scientific terminates pension plan, transfers $17.7M obligations via annuity
Pension plan terminated effective April 30, 2024; $17.7M in obligations transferred via group annuity contracts.
-
CEO Thomas Hull III enters $250K retention bonus with 3-year clawback
Retention bonus of $250,000 payable within 10 days of March 18, 2024 effective date.
-
Kewaunee Q3 FY2024 EPS $0.85 vs $0.25 YoY; net income triples despite 23% sales drop
Sales $46.8M, down 23% YoY from $60.8M; net income $2.5M vs $0.7M.
-
Kewaunee Scientific to report Q3 FY2024 earnings on March 6, 2024 after market close
Earnings release scheduled for Wednesday, March 6, 2024 after close of trading.
-
Kewaunee Scientific swings to Q2 profit of $2.7M; EPS $0.93 vs -$0.09
Sales $50.4M, down 7.6% YoY; net earnings $2.7M vs loss of $243K.
-
Kewaunee Scientific to release Q2 FY2024 earnings on Dec 6, 2023
Q2 fiscal 2024 results scheduled for release on December 6, 2023 after market close.
-
Kewaunee Scientific Q1 net earnings $2.47M vs loss of $0.75M YoY; EPS $0.86 vs ($0.27)
Net earnings of $2.47M ($0.86 diluted EPS) vs net loss of $0.75M ($0.27 loss) in prior Q1.
-
Kewaunee shareholders approve 2023 Omnibus Incentive Plan with 374,633 new shares
Plan authorizes 374,633 shares; approved by 1,419,893 for, 498,027 against.
-
Investor presentation and script posted to company website and furnished as Exhibits 99.1 and 99.2.
-
Kewaunee Scientific posts Q4 profit of $0.34/share; FY revenue up 30% to $219.5M
Q4 net earnings $1,005,000 ($0.34 diluted EPS) vs net loss of $362,000 ($0.13 loss) in prior year.
-
Kewaunee Q3 net income $723K ($0.25 EPS) vs loss; sales up 49.7%
Net earnings $723K ($0.25 diluted EPS) vs net loss $1,319K (-$0.47); sales $60.8M, +49.7% YoY.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.45 · Most common event earnings